Enzyme linked immunoassay with diffusion rate limiting medium
Patent Information
- Application Number
- HK62026124448
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-06-08
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480044665.4 (22) Application Date 2024.09.19 (30) Priority Data 32023079605.6 2023.09.22 HK (85) PCT International Application Entering National Phase Date 2025.12.30 (86) PCT International Application Application Data PCT / IB2024 / 059086 2024.09.19 (87) PCT International Application Publication Data WO2025 / 062323 EN 2025.03.27 (71) Applicant: Ariane Biotechnology Co., Ltd. Address: Hong Kong, China (72) Inventors: Zeng Zhiwei, Ye Yazhi (74) Patent Agency: Shenzhen Eagle Wing Intellectual Property Agency Co., Ltd. 44658 Patent Attorneys: Huang Xing'er, Wang Yijin (51) Int.Cl. G01N 33 / 569 (2006.01) (54) Invention Title: Enzyme-Linked Immunoassay Using a Diffusion Rate Limiting Medium (57) Abstract: One aspect of the present invention provides a method for detecting a target organism in a sample, the method comprising: a. optionally immobilizing the target organism on a solid phase; b. incubating the target organism with one or more reporter enzyme detection probes to form one or more target organism-enzyme detection probe complexes; c. removing any unbound reporter enzyme detection probes; d. contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products in the diffusion rate limiting medium; e. detecting the one or more detectable products by detecting visible spots. Claims 2 pages, Description 21 pages, Drawings 19 pages, CN 121752900 A 2026.03.27 CN 1 21 75 29 00 A 1. A method for detecting a target organism in a sample, the method comprising: a. optionally immobilizing the target organism on a solid phase; b. incubating the target organism with one or more reporter enzyme detection probes to form one or more target organism-enzyme detection probe complexes; c. removing any unbound reporter enzyme detection probes; d. contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products; ande. Detecting the one or more detectable products by detecting visible spots; wherein the diffusion rate limiting medium is any suitable medium that reduces the diffusion rate of the one or more detectable products and thereby allows the formation of the visible spots. 2. The method of claim 1, wherein step b) comprises incubating the target organism with one or more major detection agents specific to the target organism before incubating with the one or more reporter enzyme detection probes to form the one or more target organism-enzyme detection probe complex. 3. The method of claim 2, wherein the one or more major detection agents bind to one or more surface ligands of the target organism, one or more surface markers of the target organism, or one or more target substances secreted by the target organism, and wherein the major detection agent is an antibody or a binding fragment thereof, or an antigen. 4. The method of any one of claims 1 to 3, wherein if the target organism expresses an endogenous enzyme that is the same as or similar to the reporter enzyme of the one or more reporter enzyme detection probes, then step b) further comprises contacting the target organism with an inhibitor of the endogenous enzyme. 5. The method of any one of claims 1 to 4, wherein the target organism is a cell or a portion thereof, or a microorganism or a portion thereof. 6. The method of any one of claims 1 to 5, wherein the solid phase is a reaction vessel, bead, or plate, and wherein the surface of the solid phase is selected from metals, gold, stainless steel, plastics, glass, silica, polycarbonate, polyester, PVDF, polystyrene, nitrocellulose, and cellulose. 7. The method of any one of claims 1 to 6, wherein the target organism is immobilized by direct binding to the solid phase, or indirectly immobilized on the solid phase by a capture molecule coupled to the solid phase binding the target organism. 8. The method of claim 7, wherein the capture molecule is an antibody, antigen, or ligand. 9. The method of any one of claims 1 to 8, wherein the diffusion rate limiting medium is a semi-solid medium, a membrane, or a viscous fluid. 10. The method of claim 9, wherein the semi-solid medium is selected from the group consisting of agar, agarose, hydrogel, gelatin, silicone gel, cellulose derivatives, and SDS-PAGE gel. 11. The method of claim 9, wherein the membrane is selected from the group consisting of paper membranes, fibrous membranes, cellulose membranes, and plastic membranes. 12. The method of claim 9, wherein the viscous fluid is selected from the group consisting of cellulose derivatives, polysaccharide or monosaccharide gels (syrups, low-concentration hydrogels, cassava gels, guar gum, xanthan gum, gum arabic, hydroxyethyl cellulose, HPC (hydroxypropyl cellulose)), and low-concentration hydrogels. 13. The method of any one of claims 1 to 12, wherein the one or more reporter enzyme detection probes are compatible with the claimed method.Requesting book 1 / 2 page 2 CN 121752900 A The target organism has one or more surface ligands, one or more surface markers of the target organism, one or more target substances secreted by the target organism, or one or more major detection agents bound together, wherein the reporter enzyme detection probe is selected from antibodies or their binding fragments, antigens, drugs, or peptides, which are directly or indirectly conjugated to an enzyme or catalyst that can change color upon contact with a substrate. 14. The method of any one of claims 1 to 13, wherein the substrate is selected from the group consisting of tetramethylbenzidine (TMB), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), p-nitrophenol (PNPP), 3,3'-diaminobenzidine (DAB), 4-(trifluoromethyl)umbelliferyl ketone phosphate, 4-methylumbelliferyl ketone-β-D-galactopyranoside (Mu-Gal), adamantyl 1,2-dioxane phosphate, o-nitrophenyl-β-D-galactopyranoside (ONPG), nitroblue tetrazolium (NBT), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), nitroblue tetrazolium chloride (NBT), N-acetyl-Leu-Glu- His-Asp-7-amino-4-trifluoromethylcoumarin, N-acetyl-Leu-Glu-Thr-Asp-7-amino-4-trifluoromethylcoumarin and 3-oxo-3H-phenoxazine-7-yl-butyrate (butyrate halogen). 15. A method for quantifying the amount of a target organism in a sample, the method comprising a. detecting the target organism according to any one of claims 1 to 14; and b. quantifying the amount of the target organism in the sample based on the number of visible spots. Claims 2 / 2 pages 3 CN 121752900 A Enzyme-Linked Immunoassay Using Diffusion Rate Limiting Media Technical Field
[0001] The present invention relates to enzyme-linked immunosorbent assays using diffusion rate limiting media. Specifically, the present invention relates to a method for detecting target organisms in a sample. Background Art
[0002] Different research procedures and assays are used in fields such as medicine and molecular biology. For example, assays are widely used in immunology to determine the activation rate of cells in response to vaccines, infections, allergens, etc. Assays involving antibodies as key components are typically referred to as immunoassays, which are preferred analytical methods for the repetitive quantitative analysis of biomolecules of biomedical importance, such as peptide molecules. Examples of immunoassays include, but are not limited to, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot assay (ELISpot), and FluoroSpot assay.
[0003] ELISpot is used to quantify cells with targeted secretion markers. It is limited to secretion markers and only requires the capture of secretions via a specific probe. The capture antibody binds to the membrane on the platform / plate, and thus also binds the secretion to the membrane. The cells are then washed away, and the platform is treated with the probe and substrate, resulting in stained spots on the membrane at the binding sites in the presence of the secretion marker. Three main problems can be found with ELISpot. First, the membrane coating on the platform significantly increases the cost per assay compared to using a standard platform. Second, the requirement to wash away cells means that surface markers cannot be targeted. Third, this means that target cells are removed and cannot be harvested for further use.
[0004] ELISA is a quantitative and qualitative immunoassay commonly used to detect biomolecules such as antigens, antibodies, cytokines, etc., throughout a cell population. Cell-based ELISA can also detect cell surface markers. However, during ELISA assays, cells are either fixed (the process by which cells are perforated and thus die) or washed away. Quantitative ELISA is limited to relative quantification by comparison with the colorimetric concentration of pure reference standards. Therefore, it cannot distinguish the exact number of cells presenting the target cell surface marker or secretion marker. As a population study, a sufficient detection limit must be reached to give detectable results. Small amounts of positive results in a large sample may go undetected, resulting in false negatives.
[0005] Flow cytometry is used to quantify cells with specific cell surface markers in a large population. Recently, flow cytometry has also been used for cell secretion markers, but more steps are required to label the cell surface markers before the secretion markers can be captured. The equipment used for this assay is very expensive, and although cells can be sorted after analysis, the process can result in a high percentage of cell loss and individual cell separation is not possible without additional separation techniques.
[0006] Therefore, there is a significant unmet need for an inexpensive single assay that can be used to analyze cell surface markers, cell secretion markers, or a combination of both, which can separate cells into single cells and maintain cell viability. It requires almost no expensive equipment and can be performed on any platform format, such as Pieter plates, 96-well plates, or even clear vials.
[0007] One aspect of the present invention provides a method for detecting a target organism in a sample, the method comprising:
[0008] a. optionally immobilizing the target organism on a solid phase;
[0009] b. incubating the target organism with one or more reporter enzyme detection probes to form one or more target organism-enzyme detection probe complexes;
[0010] c. removing any unbound reporter enzyme detection probes;
[0011] d. Contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products; and
[0012] e. Detecting the one or more detectable products by detecting visible spots;
[0013] wherein the diffusion rate limiting medium is any suitable medium that reduces the diffusion rate of the one or more detectable products and thereby allows the formation of the visible spots.
[0014] Another aspect of the invention provides a method for quantifying the amount of a target organism in a sample, the method comprising
[0015] a. detecting the target organism according to the method of the invention; and
[0016] b. quantifying the amount of the target organism in the sample based on the number of visible spots. Brief Description of the Drawings FIG1
[0017] [FIG.1] illustrates a general concept of a method for detecting a target organism in a sample according to the invention. Figure 2
[0018] [Figure 2] shows [A] an ELISpot for detecting target substances secreted by a target organism; [B] a method according to the invention for detecting target substances secreted by a target organism via platform selective capture; [C] a method according to the invention for detecting target substances secreted by a target organism via surface marker tagging. Figure 3
[0019] [Figure 3] shows a method according to the invention, wherein two or optionally three markers can be used to specifically identify cells with targeting properties that elicit a single positive or negative response, such as the presence or absence of a colorimetric change. Figure 4
[0020] [Figure 4] shows a method according to the invention, wherein three markers are used to specifically identify cells with a combination of multiple properties that elicit multiple possible responses. Reactions using different colorimetric substrates, fluorescent substrates, or other substrates to products can produce combinations of responses, and only some are depicted here. [A] shows responses from all three markers; [B] shows responses from two of the three possible markers; [C] shows responses from only one of the three possible markers. This is merely an example of a possibility, and other combinations are possible. Figure 5
[0021] [Figure 5] shows two additional embodiments of the invention as described in [Figure 1], depicting alternative applications of the diffusion rate limiting medium and substrate. [A] shows an example application of the diffusion rate limiting medium on a sample that has already been treated with a reporter enzyme detection probe. [B] shows an example application in which a platform containing the diffusion rate limiting medium can be pre-prepared, and a sample pre-treated with a reporter enzyme detection probe is applied to the surface. Figure 6
[0022] [Figure 6] shows a graphical depiction of the relationship between the number of countable visible spots (y-axis) and the diffusion rate of the substrate and detectable product (x-axis), controlled by variables listed herein. Figure 7
[0023] [Figure 7] shows representative images of methylene blue diffusion through the following different agar gel compositions: 0.25%, 0.5%, 0.75%, 1%, and 1.5% (w / v) agar in water. Each gel composition was prepared 3 times (except for 0.5% (n = 2)), and 5 methylene blue diffusion measurements (pixel diffusion distance shown by white arrows) were recorded for each gel on page 2 / 21 of the specification, CN 121752900 A. [Figure 8] shows a summary of the methylene blue diffusion distance after 1 hour. Figure 8
[0024] [Figure 8] shows a graph of the relationship between methylene blue diffusion and agar composition. (n=3). Figure 9
[0025] [Figure 9] shows the following photographs taken with a macroscopic CCD camera: rows i) ELISA wells, ii) ELISA wells and iii) schematic depictions of different layers in the experiment, wherein columns A) and B) (read from bottom to top) are coated with (1) rabbit anti-human CD27 primary antibody, (2) CD27+ cells, (3) rabbit anti-human CD27 antibody labeling and (4) HRP-conjugated goat anti-rabbit Fc region secondary antibody. Column C) (read from bottom to top) is coated with (1) rabbit monoclonal antibody (mAb) anti-CD27 primary antibody and (2) CD27+ cells, and is not further labeled. Images Ai) and Ai) were developed using 50:50 (TMB:2xRPMI), Bi) and Ci) were developed using 1:1:2 (4xRPMI:1.2% agarose:TMB), and Bi) and Ci) were developed using 1:1:2 (4xRPMI:1.2% agarose:TMB). Each experiment was performed in triplicate, n=3. Figure 10
[0026] [Figure 10] shows a summary of the number of visible spots (dots) counted when different concentrations of agar were used as diffusion rate limiting media (developing media). Figure 11
[0027] [Figure 11] shows a summary of the number of visible spots (dots) counted when different concentrations of Carbopol 940 were used as diffusion rate limiting media (developing media). Figure 12
[0028] [Figure 12] shows visible spots (dots) magnified 100x through the ELISA wells using an upward-looking microscope. Figure 13
[0029] [Figure 13] summarizes the results of the method of the present invention using different diffusion rate limiting media (chromogenic media) in the final stage of the assay. Figure 14
[0030] [Figure 14] shows a graphical depiction of the non-immobilized form of the method of the present invention. CD27 positive cells were treated with rabbit anti-human...CD27 antibody, followed by HRP-conjugated goat anti-rabbit Fc region antibody, is fully coated. Figure 15
[0031] [Figure 15] shows the following photographs taken with a macroscopic CCD camera: A) Microscope slide containing 10 µL of CD27-labeled cells mixed with 0.028% Carbopol-ELISA-specific TMB mixture; B) Microscope slide containing 10 µL of CD27-labeled cells mixed with 0.028% Carbopol-ELISA-specific TMB mixture; C) Microscope slide containing 10 µL of negative control mixed with 0.028% Carbopol-ELISA-specific TMB mixture; and D) Microscope slide containing 10 µL of negative control mixed with 0.028% Carbopol-ELISA-specific TMB mixture. Figure 16
[0032] [Figure 16] shows the following photographs taken with a top-view microscope: A) 10x magnification of multiple visible spots (dots) formed on the microscope slide and B) 100x magnification of visible spots formed at target cell sites near non-target cells, the absence of color indicating no product formation. Figure 17
[0033] [Figure 17] shows the following photographs taken with a macroscopic CCD camera: A) negative control, in which CD27 positive cells were immobilized with rabbit anti-human CD27 antibody and not labeled with SARS-Cov-2 antigen; and B) antigen-specific memory B cells, which were CD27 positive cells immobilized with rabbit anti-human CD27 antibody and labeled with SARS-Cov-2 spike protein and nucleocapsid protein. Each experiment was performed in triplicate, n=3. Figure 18
[0034] [Figure 18] shows a bar chart of the data from Table 1 of negative controls and SARS-CoV-2 specific memory B cells, represented as points per 5 x 10⁵ whole PBMCs. Example Description
[0035] All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference in their entirety. The publications and applications discussed herein are provided only for their disclosure prior to the filing date of this application. Nothing herein should be construed as an admission that the invention does not enjoy rights based on prior inventions prior to such publications. Furthermore, the materials, methods and examples described are merely illustrative and not intended to be limiting.
[0036] In case of conflict, this specification, including the definitions, shall prevail. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this subject matter pertains. As used herein, the following definitions are provided to facilitate understanding of the invention.
[0037] The term “comprise” is generally used in the sense of including, that is, allowing the presence of one or more features or components. Similarly, as used in the specification and claims, the word “comprise” can include similar embodiments described as “consisting of” and / or “substantially consisting of”. The terms “including,” “comprising,” or “having,” and variations thereof, are intended to cover the elements listed thereafter and their equivalents, as well as additional elements. Embodiments described as “comprising,” “including,” or “having” specific elements are also considered to be “substantially consisting of those specific elements” and “consisting of those specific elements.”
[0038] As used in the specification and claims, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” also include plural indicators.
[0039] As used in the specification and claims, the term “and / or” as used in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A,” and “B.”
[0040] As used herein, the term "chromophore" refers to a marker that causes a color change within the visible spectrum and can be observed without the aid of instrumentation.
[0041] As used herein, the term "fluorophore" refers to a molecule that exhibits fluorescent properties. Fluorophores absorb photons and emit photons of lower energy, and visualization requires the aid of fluorescence instrumentation.
[0042] As used herein, the term "chemiluminescence" refers to the emission of light resulting from a chemical reaction that transforms a substrate into a product. The product is in an excited state and will emit light when it returns to a baseline state. Visualization requires the aid of a low-light environment (e.g., a darkroom or dark box).
[0043] As used herein, the term "reporter enzyme detection probe" comprises a reporter enzyme component containing enzyme activity, said reporter enzyme component being coupled to a detection probe component containing a target binding moiety. The reporter enzyme is optionally a peroxidase, such as horseradish peroxidase, or a phosphatase, such as alkaline phosphatase. Although any stable enzyme that produces an ionizable product may be used, including, for example, lyases, hydrolases, synthases, oxidoreductases, dehydrogenases, oxidases, transferases, isomerases, ligases, proteases such as trypsin, proteinases, peroxidases, glucose oxidases, myeloperoxidases, oxidases, monooxygenases, cytochromes, phosphatases (such as alkaline phosphatase), decarboxylases, lipases, caspases, amylases, peptidases, transaminases, and kinases. Additional enzymes may include DNA or, as per the specification, page 4 / 21, 7 CN.121752900 A RNA polymerase, TAQ, restriction endonuclease, Klenow fragment, DNA ligase. The target-binding moiety can be a primary target-binding moiety that selectively binds to the target substance (e.g., a biopolymer, such as an antibody or antigen), or a secondary target-binding moiety that selectively binds to the primary detection agent. For example, the secondary target-binding moiety can contain a biopolymer, such as an antibody or antigen, that binds to the antibody-based primary detection agent. Alternatively, the secondary target-binding moiety can contain avidin or streptavidin that selectively binds to a biotinylated primary detection agent (e.g., a biotinylated primary detection agent). In addition to antibodies and antibody-binding fragments, other biopolymer target-binding moieties that specifically bind to the target substance or primary detection agent are provided, including, for example, antibody mimics, aptamers, binding peptides (e.g., receptors), and binding peptide mimics, nucleic acids, carbohydrates, and / or lipids. Examples include nucleic acid and / or peptide aptamers, avidins, and anticalcitonins. For example, according to embodiments, the primary antibody can be linked to an enzyme, antigen, etc., provided that the secondary antibody is specific to the linked molecule and attaches to an enzyme different from the primary antibody.
[0044] As used herein, the term "primary assay" means an agent that selectively binds to a surface ligand of a target organism, a surface marker of a target organism, or a target substance secreted by a target organism (e.g., a secretory marker of the target organism). The primary assay may optionally be coupled to a detectable label, such as biotin. In addition to antibodies and antibody-binding fragments, other primary assays that specifically bind to surface ligands, surface markers, or target substances are provided, including, for example, antibody mimics, binding peptides (e.g., receptors), binding peptide mimics, nucleic acids and peptide aptamers, affinity molecules, and anticalcitonins.
[0045] This disclosure relates to a novel enzyme-linked immunosorbent assay (ELISA) that uses a diffusion rate limiting medium along with a substrate in a final stage to allow the accumulation of product concentration around the reaction site and the generation of detectable spots from one or more target targets. Different combinations of capture antibodies (optional), primary antibodies, enzyme probes (e.g., horseradish peroxidase, alkaline phosphatase, etc.), substrates (e.g., chromophores, fluorophores, chemiluminescent substrates and / or others), and containers (e.g., 96-well plates, slides, etc.) can be fitted into a system to detect cell surface markers and secretion markers at a fraction of the cost of conventional methods. Furthermore, depending on the combination used, samples can remain viable for other experiments, and microscopic examination can be performed on transparent containers (e.g., 96-well plates).
[0046] One aspect of the invention provides a method for detecting target organisms in a sample, the method comprising:
[0047] a. optionally immobilizing the target organism on a solid phase;
[0048] b. incubating the target organism with one or more reporter enzyme detection probes to form one or more...
[0049] c. Removing any unbound reporter enzyme detection probes;
[0050] d. Contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products in the diffusion rate limiting medium; and
[0051] e. Detecting the one or more detectable products by detecting visible spots;
[0052] wherein the diffusion rate limiting medium is any suitable medium that reduces (limits) the diffusion rate of the one or more detectable products and thereby allows the formation of the visible spots.
[0053] In some embodiments, step b) includes incubating the target organism with one or more major detection agents specific to the target organism before incubating with the one or more reporter enzyme detection probes to form the one or more target organism-enzyme detection probe complexes. In another embodiment, one or more primary detection agents bind to one or more surface ligands of the target organism, one or more surface markers of the target organism, or one or more target substances secreted by the target organism (e.g., secretory markers of the target organism). In a preferred embodiment, page 5 / 21 of CN 121752900 A, one or more primary detection agents are antibodies or their binding fragments, or antigens. In some embodiments, one or more primary detection agents comprise biotin conjugated to an antibody or its binding fragment that is specific to the target organism or target substance.
[0054] In some embodiments, one or more surface markers of the target organism are selected from, but not limited to, the following list:
[0055] ■ B cells (target organism): CD27, CD19, CD21, CD20, CD38, CD23, CD138, IgA, IgG, IgM, B cell receptor.
[0056] ■ T cells (target organism): CD4, CD8, T cell receptor, CD44, CD25, CD30.
[0057] ■ Adult mesenchymal stem cells (target organisms): CD10, CD13, CD73, CD105, CD271.
[0058] ■ Embryonic stem cells (target organisms): CD15, SSEA-3, CD324, CD90, CD117, CD29.
[0059] In some embodiments, one or more target substances secreted by the target organism are selected from (but not limited to) the following group, including:
[0060] ■ B cells (target organisms): IgA, IgG, IgM, INF-γ, IL-6, IL-10, IL-13, lymphotoxin (TNF family cytokines).
[0061] ■T cells (target organisms): IL-1, IL-4, IL-5, IL-6, IL-9, IL-13, TGFβ.
[0062] In some embodiments, step b) further includes inhibiting the endogenous enzyme activity of the target organism (e.g., human cells and E. coli). Inhibiting the endogenous enzyme activity of the target organism is to reduce the possibility of background false positives (false spots) generated by the endogenous enzyme activity of the target organism. In a specific embodiment, if the target organism expresses an endogenous enzyme (e.g., peroxidase) that is the same as or similar (in activity) to the reporter enzyme of the one or more reporter enzyme detection probes, then step b) further includes contacting the target organism with an inhibitor of the endogenous enzyme (e.g., a peroxidase inhibitor). For example, peroxidase inhibitors are used to reduce background false positives (false spots) generated by the endogenous peroxidase activity of some specific target organisms (e.g., human cells and E. coli).
[0063] Figures 1 to 5 illustrate different configurations of the method of the present invention. In [Figure 1], a target organism with a specific marker (depicted as a surface marker in this example) is labeled with a marker-specific reporter enzyme detection probe. This is mixed to form a suspension within a diffusion rate-limiting medium containing a substrate specific to the reporter enzyme. As the reporter enzyme converts the substrate into a detectable product, a region of higher concentration relative to the remainder of the diffusion rate-limiting medium is created due to the restricted diffusion of the detectable product, resulting in a visible spot.
[0064] In some embodiments, the target organism is a cell or a portion thereof, or a microorganism or a portion thereof. The target organism (such as a cell or microorganism) can be alive (live) or dead. Preferably, if the target organism is not alive, the surface ligand or surface marker of the target organism should be intact.
[0065] In some other embodiments, the detection of the target organism can be performed by detecting a target substance secreted by the target organism. According to this embodiment, the target substance can act as a ligand for the reporter enzyme detection probe or the primary detection agent. In some embodiments, the target substance is selected from the group consisting of biopolymers, biomarkers, and proteins secreted by cells or microorganisms. In other embodiments, the target substance is selected from the group consisting of tumor markers, autoantigens, hormones, chemokines, cytokines, cardiac proteins, nucleic acid molecules, lipids, and carbohydrates. Typically, the method according to the invention for detecting target substances secreted by a target organism can be performed as follows: a primary detection agent is adhered to the cell surface for initial selection, followed by the attachment of a target substance capture antibody to the primary detection agent via a scaffold system (e.g., biotin-streptavidin) to allow the secretion of the target substance, and then the target is labeled with a reporter enzyme detection probe.The other end of the substance (see [Figure 2]). Optionally, the cells secreting the target substance can be immobilized on a solid phase as disclosed below (see [Figure 3]). Specification 6 / 21 pages 9 CN 121752900 A
[0066] In some embodiments, the sample is a body fluid, body tissue, or any material or composition that may contain a target organism (such as cells or microorganisms), preferably a blood sample.
[0067] In some embodiments, the target organism is immobilized by directly binding to the solid phase (optionally by adsorption to the solid phase), or indirectly immobilized on the solid phase by a capture molecule of the target organism coupled to the solid phase. The capture molecule coupled to the solid phase binds to the same or different surface ligands or surface markers of the target organism compared to one or more reporter enzyme detection probes or one or more primary detection agents. In a preferred embodiment, the capture molecule is an antibody or its binding fragment, antigen, or ligand. For example, the capture molecule is an anti-CD27 antibody. The capture molecule typically immobilizes T cells, NK cells, memory B cells, plasmablast B cells, and plasma B cells from blood samples onto a plate. Of all these cell types, only memory B cells and plasmablast B cells express B cell receptors and bind directly to reporter enzyme detection probes or primary detection agents. In some embodiments, the capture molecule allows for selective (specific targeting) of target organisms.
[0068] In some embodiments, the solid phase is a reaction vessel, bead, platform, or plate. Exemplary reaction vessels may be selected from the group consisting of 96-well plates, 6-well plates, Pieter dishes, and tissue-suitable tubes (such as Falcon tubes). In other embodiments, the surface of the solid phase is selected from metals, gold, stainless steel, plastics, glass, silica, polycarbonate, polyester, PVDF, polystyrene, nitrocellulose, and cellulose.
[0069] In some embodiments, the incubation in step b) is performed in solution under conditions used to form one or more target organism-enzyme detection probe complexes. The solution used for incubation in step b) may be selected from (but is not limited to) the following group, including RPMI1640 + 10% fetal bovine serum, DMEM, HEPES, MEM, DMEM F12, IMDM, M199, Ham's F12, Ham's F10, HPLM, fetal bovine serum, and human serum. The incubation conditions in step b) are typically 30 minutes to 4 hours, preferably 1 hour to 3 hours; and the temperature may be in the range of 20°C to 40°C; preferably 25°C to 40°C, most preferably 35°C to 40°C.
[0070] The one or more reporter enzyme detection probes are associated with one or more surface ligands of the target organism, one or more surface markers of the target organism, one or more target substances secreted by the target organism, or...The one or more primary detection reagents are combined. In other embodiments, the reporter enzyme detection probe is selected from antibodies or their binding fragments, antigens, drugs, or peptides, which are directly or indirectly conjugated to an enzyme or catalyst that can change color upon contact with a substrate.
[0071] In embodiments, the reporter enzyme detection probe comprises a primary target-binding moiety (e.g., for direct binding to a target organism or for direct binding to a target substance) or a secondary target-binding moiety (e.g., for indirect binding to a target organism or for indirect binding to a target substance) and a reporter enzyme containing enzymatic activity, wherein the target-binding moiety is covalently bound to the reporter enzyme.
[0072] In another embodiment, the reporter enzyme is or contains lyases, hydrolases, synthases, oxidoreductases, dehydrogenases, oxidases, transferases, isomerases, ligases, proteases (e.g., trypsin, protease), peroxidases, glucose oxidases, myeloperoxidases, oxidases, monooxygenases, cytochromes, alkaline phosphatases, decarboxylases, lipases, caspases, amylases, peptidases, transaminases, and / or kinases. In another embodiment, the reporter enzyme is selected from DNA or RNA polymerases, TAQ, restriction endonucleases, Clenno fragments, and DNA ligases. In a preferred embodiment, the reporter enzyme is or contains horseradish peroxidase or alkaline phosphatase.
[0073] In some embodiments, the reporter enzyme detection probes are different, i.e., each reporter enzyme detection probe is specific to a specific marker (i.e., a specific surface marker, a specific surface ligand, or a specific secretion marker) (see, for example, [Figure 4]). In some embodiments, using more than one different reporter enzyme detection probe allows targeting a target organism with different markers (surface markers, surface ligands, and / or secretion markers). In some other embodiments, using more than one different reporter enzyme detection probe allows targeting different target organisms with different markers (surface markers, surface ligands, and / or secretion markers). Therefore, according to one aspect, the method of the present invention allows for the detection of one or more target organisms in a sample, as described on page 7 / 21 of the specification (CN 121752900 A), the method comprising:
[0074] a. optionally immobilizing the one or more target organisms on a solid phase;
[0075] b. incubating the one or more target organisms together with one or more reporter enzyme detection probes to form one or more target organism-enzyme detection probe complexes;
[0076] c. removing any unbound reporter enzyme detection probes;
[0077] d. contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes with the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products; and
[0078] e. Detection of the one or more detectable products by detecting visible spots;
[0079] wherein the diffusion rate limiting medium is any suitable medium that reduces the diffusion rate of the one or more detectable products and thereby allows the formation of the visible spots.
[0080] In some embodiments, any unbound reporter enzyme detection probes are removed by washing the solid phase.
[0081] According to a specific embodiment, any unbound reporter enzyme detection probes are removed by centrifugation when the target organism is not immobilized on the solid phase. Typically, washing is performed in a container, such as a tissue culture-grade sterile tube (e.g., a 15 mL Falcon tube). The target organism, such as cells (which have a higher density), will settle under centrifugal force (forming a precipitate), and the unbound reporter enzyme detection probes will remain in the solution. The supernatant (containing the unbound reporter enzyme detection probes) is discarded and fresh culture medium is added to further dilute the unbound reporter enzyme detection probes. The precipitated cells are resuspended, and the process is repeated 3 times. Finally, the labeled and unlabeled target organisms (e.g., cells) remain in the culture medium. The unbound reporter enzyme detection probes are discarded.
[0082] The substrate is a molecule that is catalyzed by the reporter enzyme to provide a colorimetric, fluorescent, or chemiluminescent detectable product. The detectable product provides a visible spot. In some embodiments, the substrate is selected from (but is not limited to) the group consisting of tetramethylbenzidine (TMB), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), p-nitrophenol (PNPP), 3,3'-diaminobenzidine (DAB), 4-(trifluoromethyl)umbelliferyl ketone phosphate, 4-methylumbelliferyl ketone β-D-galactopyranoside (Mu-Gal), adamantyl 1,2-dioxane phosphate, o-nitrophenyl-β-D-galactopyranoside (ONPG), nitroblue tetrazolium (NBT), 2, 2'-Diammonium bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), o-phenylenediamine dihydrochloride (OPD), nitrogen blue tetrazolium chloride (NBT), N-acetyl-Leu-Glu-His-Asp-7-amino-4-trifluoromethylcoumarin, N-acetyl-Leu-Glu-Thr-Asp-7-amino-4-trifluoromethylcoumarin, and 3-oxo-3H-phenoxazine-7-yl-butyrate (butyrate halogen).
[0083] According to the method of the present invention, one or more identical or different substrates may be used. Typically, when more than one different reporter enzyme detection probe is used, more than one different substrate is used. Targeting the biomarkers of the target organism makes them distinguishable. Using more than one substrate allows the detection of different biomarkers (surface biomarkers, surface ligands, etc.).A target organism (surface marker, surface ligand, and / or secretory marker) or a different target organism with different markers (surface marker, surface ligand, and / or secretory marker).
[0084] [Table 1] Non-exhaustive examples of substrates 8 / 21 pages 11 CN 121752900 A
[0085] The diffusion rate limiting medium (DRLM) is designed to carry the substrate (which ultimately generates a visible spot when the reporter enzyme of the reporter enzyme detection probe is catalyzed); to be porous to allow the flow of unconverted substrate and converted detectable product (i.e., before and after reporter enzyme catalysis); to slow the diffusion rate of the converted substrate, concentrate the product into a detectable product, thereby allowing the formation of a visible spot around the site of the reporter enzyme probe reaction site; and to provide an interface for the reaction between the reporter enzyme (part of the reporter enzyme detection probe, which binds to the target organism) and the substrate. The diffusion rate limiting medium (DRLM) is any suitable medium that limits the diffusion rate by physical properties (e.g., pore size) or by chemical properties (e.g., charge, hydrophobicity, pH, etc.).
[0086] In contrast to ELISpot and ELISA (where the product of enzyme conversion is absorbed into the membrane of the ELISpot well to form a staining spot (see [Figure 2A])) or absorbed into ELISA (which would form a stain throughout the solution), the method of the present invention uses a diffusion rate limiting medium to slow the diffusion of the product and trap it around cells already labeled by the reporter enzyme detection probe, thereby allowing the formation of detectable spots within the diffusion rate limiting medium (DRLM).
[0087] In some embodiments, the diffusion rate limiting medium (DRLM) may also provide an environment conducive to the activity of the target organism, for example, by providing osmolar regulation and pH buffering, as well as providing nutrients.
[0088] In another embodiment, the diffusion rate limiting medium (DRLM) is non-toxic (e.g., for non-endpoint applications).
[0089] A diffusion rate limiting medium (DRLM) that reduces the diffusion rate of the detectable product relative to the target organism can be described in the specification 9 / 21 pages 12 CN 121752900 A They can be located in different positions. That is, the target organism can be above the DRLM ([Fig. 5A]), below the DRLM ([Fig. 5B]), or inside the DRLM ([Fig. 1]).
[0090] In some embodiments, the diffusion rate limiting medium is a semi-solid medium, a membrane, or a viscous fluid. According to an embodiment, the semi-solid medium is selected from the group consisting of agar, agarose, hydrogels (e.g., Carbopol 940, 2NapFF), gelatin, silicone gel, cellulose derivatives, and SDS-PAGE gel. In another embodiment, the membrane is selected from the group consisting of paper membranes, fibrous membranes, cellulose membranes, and plastic membranes. In another embodiment, the viscous fluid is selected from the group consisting of cellulose derivatives (carboxymethyl methacrylate, car ..., polysaccharide or monosaccharide gels (syrups, low-concentration hydrogels, cassava gels, guar gum, gellan gum, xanthan gum, gum arabic, hydroxyethyl cellulose, HPC (hydroxypropyl cellulose)) and low-concentration hydrogels.
[0091] In some embodiments, the detectable product is a chromogenic, chemiluminescent, or fluorescent molecule. In other embodiments, the detectable product may have radiological and / or electrochemical properties.
[0092] Visible spots can be detected manually with a microscope or automatically with a suitable device such as a macro camera. If the visible spots are outside the visible spectrum visible to the human eye, they are automatically detected with a suitable device adapted to such a spectrum, such as a macro camera. In the case of chromogenic data, typically, photographs of individual wells on a 96-well plate can be taken with a device such as a macro camera, and the visible spots can be quantified using software. If chemiluminescence or fluorescence is used, the visible spots can be detected and quantified using specialized filters and lamps for fluorescence and chemiluminescence.
[0093] The size and formation of the visible spots are controlled by the diffusion rate of the substrate and / or the detectable product. The diffusion rate is typically affected by the following: the physical properties of the diffusion rate limiting medium (DRLM), such as porosity; chemical properties, such as charge or pH; incubation temperature, which may be important for the reporter enzyme, and where higher temperatures provide a faster diffusion rate; incubation duration; chemical and physical properties of the diffusion rate limiting medium (DRLM) and the substrate (and their interactions); reporter enzyme kinetics (the rate at which the reporter enzyme converts the substrate and thus forms a visible spot); and the effective concentration of substrate supplied for the reaction. In a preferred embodiment, a high concentration of detectable product is formed around the target organism by being trapped by a slow diffusion rate, resulting in the formation of a visible spot.
[0094] The selection of a suitable diffusion rate limiting medium (DRLM) can be made as follows. A literature search and / or experimental testing must be performed to determine the suitability of the diffusion rate limiting medium (DRLM). The following key functions of the diffusion rate limiting medium should be considered:
[0095] 1. The ability to carry substrate.
[0096] 2. Porosity and / or other chemical and / or physical properties that may affect the diffusion of substrate to the enzyme reaction site and the outward diffusion of detectable product.
[0097] 3. The ability to manipulate the properties of the diffusion rate limiting medium to influence the product diffusion rate, allowing for the accumulation of concentration around the enzyme to form a detectable visible spot.
[0098] 4. To provide an interface for the enzyme-substrate reaction.
[0099] 5. To have no inhibitory effect on the reporter enzyme / substrate reaction.
[0100] 6. For non-endpoint assays, the diffusion rate limiting medium should be non-toxic and provide conditions that maintain the activity of the target sample, including pH, osmotic pressure, and nutrients.
[0101] After selecting one or more materials, the optimal composition and concentration of the diffusion rate limiting medium should be tested. This shouldThis is done by preparing (in diluent and substrate) a series of compositions and concentrations of one or more materials that constitute the diffusion rate limiting medium. Examples of diluents are tissue culture media and / or phosphate-buffered saline (PBS) and / or solvents compatible with one or more materials, sample type, and substrate. The substrate is specifically selected for the reporter enzyme conjugated to the detection probe. A positive control reporter enzyme detection probe specific to common surface markers of the sample type should be used, according to the following specifications, page 10 / 21, 13 CN 121752900 A. The optimal diffusion rate limiting medium is evaluated based on the following variables: composition of one or more materials, concentration of one or more materials, substrate type, substrate concentration, temperature, pH, and time (other variables should also be considered, but may vary depending on the application). The results given by a series of optimization steps should appear similar to the diagram depicted in [Figure 6]. The optimal composition and concentration of one or more materials should generate the maximum number of visible spots, as described in section 2 of [Figure 6].
[0102] [Figure 6] shows a graphical depiction of the relationship between the number of dots (y-axis) and the diffusion rate of substrate and product as controlled by DRLM properties (x-axis, from high to low). The graph is divided into three zones. Zone 1 shows a low dot count where the DRLM properties are insufficient to restrict the diffusion of substrate / product. This will result in a uniform color of the medium with few detectable visible dots, or in some cases, random nonspecific product precipitation, making it impossible to count. Zone 2 shows optimal DRLM properties, and the results should show that the medium is almost unstained with a high visible dot count. Zone 3 shows a low visible dot count where the DRLM properties excessively restrict diffusion, thus limiting the diffusion of substrate / detectable product. The results of such tests will be expected to show minimal enzyme activity, thus a decreasing number of visible dots and almost no or no staining of the medium.
[0103] Variables affecting substrate and product diffusion include, but are not limited to, the physical and chemical properties of the DRLM, variations in the composition and concentration of the DRLM material, substrate type and concentration, product type and concentration, incubation temperature, and pH. Changes in each variable are expected to produce the curves depicted in [Figure 6]. Zone 1 shows the typical results when the DRLM does not adequately limit the diffusion rate, leading to rapid product diffusion into the host medium. Typical characteristics of this result include a color change in the medium, a lower than expected number of clearly countable detectable spots, and in some cases, random product precipitation. Zone 2 shows the expected results when the DRLM meets optimal conditions to form the highest amount of clearly detectable visible spots. Zone 3 shows a scenario where the DRLM and conditions limit diffusion beyond the optimal value, thus limiting the formation of detectable visible spots. The reduction in detectable visible spots may be due to insufficient substrate availability, excessively slow product diffusion causing it to remain within the microscopic boundaries of the reaction site, or other factors (such as unexpected enzyme inhibition).
[0104] Consideration should be given to the incubation duration for visible spot formation to allow for the formation of an optimal number of visible spots of detectable size / volume, without being too long and causing the visible spots to diffuse to an undetectable extent. The incubation temperature should also be considered; too low a temperature may reduce enzyme activity in a way that restricts visible spot formation. Conversely, too high a temperature may hinder or denature the enzyme, preventing the reaction from occurring and thus also reducing visible spot formation.
[0105] In the embodiments, any antibody disclosed herein may be a monoclonal antibody, a polyclonal antibody, a chimeric antibody, and / or a monospecific antibody.
[0106] In some embodiments, incubation step d) is performed between 20°C and 40°C, preferably between 23°C and 37°C. The incubation time is at least 30 minutes, preferably 30–45 minutes.
[0107] Another aspect of the present invention provides a method for quantifying the amount of a target organism in a sample, the method comprising
[0108] ■ detecting the target organism according to the method of the present invention disclosed herein; and
[0109] ■ quantifying the amount of the target organism in the sample based on the number of visible spots.
[0110] Another aspect of the present invention provides a method for selecting and separating target organisms in a sample containing different organisms, the method comprising
[0111] ■ detecting the target organism according to the method of the present invention disclosed herein; and
[0112] ■ separating the target organism.
[0113] Once a target organism is detected by the method of the present invention, it can be separated by methods known in the art, such as pipetting.
[0114] The method of the present invention for detecting one or more target organisms in a sample has many advantages compared to ELISpot. For example, the method of the present invention uses B cell-specific surface markers as targets for capture antibodies (capture molecules) to immobilize cells on a solid phase, and then uses the B cell-specific antigen-binding mechanism against a reporter enzyme detection probe. Through this procedure, targeted B cells can be isolated, and because the target is antigen binding rather than a secretory marker, there is no need to wait for cell differentiation and secretion. This results in reducing the traditional 7-day B cell assay to 1 day, and providing a true B cell count through direct detection rather than indirect detection after secretion or cell differentiation. Another advantage is that the mechanism for obtaining visible spots (i.e., color conversion) is performed in DRLM, rather than on a platform surface as in ELISpot, which limits the use of ELISpot to secretory markers and requires a more expensive membrane-coated platform; and unlike ELISA, it can separate and quantify cells. Another advantage is that the platform used can be transparent, thus allowing…Microscopic studies can be performed, and DRLM can be designed to maintain cell visibility. Furthermore, this invention enables the detection of multiple markers (multiplexing) and cell isolation of a single identical cell group in a single assay. Thus, for example, the method of this invention can replace, in one step, the following: analyzing cell surface markers in one cell group with FACS, detecting secretion markers in another cell group with ELISpot or ELISA, and then recovering cells after FACS cell sorting for dilution for cloning.
[0115] Those skilled in the art will understand that the invention described herein allows for variations and modifications beyond those specifically described. It should be understood that the invention includes all such variations and modifications without departing from its spirit or essential characteristics. The invention also includes all steps, features, and compounds individually or collectively mentioned or indicated in this specification, and any and all combinations of any two or more of said steps or features. Therefore, this disclosure should be considered illustrative rather than restrictive in all respects, and the scope of the invention is indicated by the appended claims and is intended to encompass all variations falling within the equivalent meaning and scope.
[0116] The foregoing description will be more fully understood with reference to the following examples. However, such examples are examples of practicing the methods of the present invention and are not intended to limit the application and scope of the invention. Example
[0117] 1 - Concentration of diffusion rate limiting medium affecting diffusion rate (this is example text). This example shows how the present invention can help.
[0118] Objective:
[0119] The objective of this experiment is to demonstrate how the concentration of the diffusion rate limiting medium affects the diffusion rate using agar (a possible candidate for diffusion rate limiting medium (DRLM)) and methylene blue (diffuser) as models.
[0120] Materials:
[0121] Agar and methylene blue were purchased from Sigma-Aldrich. Isopropanol (IPA) was purchased from Anaqua. Grade 1 water was generated by Merck Direct-Q® 5 UV. A climate control cabinet from MRC Laboratories was used to maintain 25°C and 50% non-condensing humidity. A macro CCD camera used for image capture was purchased from Shanghai Renyue Co., Ltd., including the calibration software S-eye. Download the data processing software, Icy software (including Image J), from https: / / icy.bioimageanalysis.org / . The SDS gel casting apparatus was purchased from Bio-Rad.
[0122] Method:
[0123] Prepare 4 mL of agar gel with the following composition: 0.25% (w / v), 0.5% (w / v), and 0.75% (w / v) in Grade 1 water.IPA (1%, 1%, and 1.5%, w / v) was added to the SDS gel casting apparatus. An IPA layer was added on top of the gel as a leveling agent, and the gel was allowed to solidify for 30 min. The IPA was then discarded and the gel was thoroughly washed with water. The top of the gel was then blotted dry by sliding lint-free paper towels between slides. 200 µL of methylene blue was added to the top of the gel, and the apparatus was placed in a climate control cabinet at 25°C and 50% non-condensing humidity for 1 hour. After 1 hour, the gel was removed from the climate control cabinet, and the remaining methylene blue was rinsed off with water and blotted dry as before. Images of each gel were taken using a fixed macro camera (page 12 / 21, CN 121752900 A). Pixel-mm calibration was performed using an ISO-certified calibration ruler, and the diffusion distance of the methylene blue after 1 hour was calculated from the number of pixels using ImageJ software.
[0124] Results:
[0125] All photos were taken using S-eye software under fixed settings and saved in jpg format. The pixel / mm correlation was determined using ImageJ with a calibration ruler. Five calibration points were taken and plotted according to the relationship between pixels and length (mm). The best-fit line (trend line) had R² = 1, and the equation was: (Y (pixels) + 8.073) / 341.7 = x (length, mm). The equation was then used to calculate the distance traveled by methylene blue.
[0126] The 1-hour diffusion distance of methylene blue for different agar compositions (0.25% (W / V), 0.5% (W / V), 0.75% (W / V), 1% (W / V), and 1.5% (W / V)) was determined by measuring the pixel length from the top of the agar to the methylene blue diffusion front (see [Figure 7]). Each agar composition was repeated three times, and five measurements were taken for each repetition. The 1-hour diffusion distance for each agar composition is plotted in [Figure 8]. The best-fit line (trend line) is consistent with the linear regression model, R2 = 0.97 (the coefficient of determination R2 > 90% or 0.9 indicates extremely strong to perfect correlation), and the equation is: y (diffusion rate in mm / h) = -0.954 x (agar composition % (W / V)) + 3.6168. As the agar composition (%, W / V) increases, the distance of methylene blue diffusion after 1 hour decreases, indicating a slower diffusion rate (mm / h).
[0127] Conclusion:
[0128] The diffusion distance of methylene blue after 1 hour decreases proportionally with the increase of agar concentration (%, W / V), and vice versa. This provides evidence that the diffusion rate within the diffusion rate limiting medium decreases with the increase of the diffusion rate limiting medium concentration.
[0129] 2 - Presence and absence of diffusion rate limiting medium
[0130] Objective:
[0131] To demonstrate that only in the final step of the determination is a suitable diffusion rate limiting medium (DRLM) present to slow down the diffusion rate.The diffusion rate of the substance and detectable product (regardless of the container) forms a clearly defined spot (visible spot).
[0132] Materials:
[0133] Rabbit anti-human CD27 antibody, HRP-conjugated goat anti-rabbit Fc region antibody and Lymphoprep were purchased from Abcam. Phosphate-buffered saline (PBS), fetal bovine serum (FCS), phenol red-containing RPMI 1640, ethylenediaminetetraacetic acid (EDTA), sodium bicarbonate (NaHCO3) and peroxidase inhibitor were purchased from Thermo Fisher Scientific. ELISA plates, trypan blue solution, phenol red-free RPMI 1640 and agar were purchased from Merck / Sigma-Aldrich. ELISA plates were purchased from Jet Biofil. 3,3',5,5'-Tetramethylbenzidine (TMB) was purchased from Mabtech. Agarose was purchased from Bio Basic.
[0134] The macroscopic CCD camera used for image capture was purchased from Shanghai Renyue Co., Ltd., including the calibration software S-eye. Data processing software, Icy software (including Image J), was downloaded from https: / / icy.bioimageanalysis.org / .
[0135] Methods:
[0136] At least 12 hours before the experiment, ELISA and ELISpot plates were coated with rabbit anti-human CD27 antibody (0.5 µg / 50 µL per well), which was prepared in phosphate-buffered saline (PBS) at pH 7. The wells were then washed six times with PBS and blocked with RPMI 1640 containing 10% FCS.
[0137] On the day of the experiment, fresh blood samples were collected from volunteers. The blood was immediately diluted (50:50) in RPMI 1640 containing 1 mg / mL EDTA. Note: RPMI 1640 containing phenol red was used for cell culture. Lymphocyte isolation was performed as follows: Diluted blood was added to the surface of 10 mL of lymphoprep solution, and then centrifuged at 800g for 30 min with the brake function off. The lymphocyte layer was extracted using a sterile disposable pipette, and fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (as per instructions on page 13 / 21, CN 121752900 A) was added to dilute the lymphocytes containing lymphoprep. The lymphocytes were centrifuged at 300g for 10 min. The supernatant was removed, and fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 was added.NaHCO3 was used to wash the cells, which were then centrifuged at 300g for 10 min. This washing process was repeated 3 times.
[0138] The lymphocytes were then resuspended in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. 100 µL of the resuspended cells was taken and diluted in 900 µL of RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (1:10 dilution). The cells were vortexed, and 100 µL of this cell suspension was taken and added to 100 µL of trypan blue solution, which was then vortexed. 20 µL of the trypan blue-suspended cells were added to a Neubauer modified counting chamber and the cells were counted.
[0139] Cells were seeded at 5 x 10⁵ cells / well in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO₃ and incubated at 37°C for 2 hours. After 2 hours, the wells were washed six times in warm (37°C) PBS. Positive CD27 cells were further labeled with rabbit anti-human CD27 antibody (0.5 µg / 50 µL per well) prepared in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO₃. Negative control wells were treated only with RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO₃. The plates were then incubated at 37°C for 2 hours. After 2 hours, the wells were washed six times in warm (37°C) PBS.
[0140] The wells were treated with a peroxidase inhibitor at 4°C for 15 min, followed by treatment at room temperature (RT) for 10 min. After peroxidase inhibitor treatment, the wells were washed six times in warm (37°C) PBS. HRP-conjugated goat anti-rabbit Fc region antibody prepared by dilution (1:1000) in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 was added to the rabbit anti-human CD27 antibody-labeled wells, and RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 was added to the negative control wells. The plate was incubated at RT for 1 h. After 1 h, the wells were washed six times in warm (37°C) PBS.
[0141] Wells without diffusion rate limiting media were prepared by taking a stock TMB solution and mixing it with an equal volume of phenol red-free 2xRPMI 1640. Add 40 µL of TMB / RPMI 1640 mixture to each well. Note: RPMI used in this working stage...1640 does not contain phenol red. The wells with semi-solid media were prepared as follows: 4xRPMI:1.2% agar (or agarose) in a 1:1:2 ratio (heated to 80°C): TMB stock solution were used to obtain 0.3% agar (or agarose) TMB semi-solid media. 40 µL of semi-solid TMB media was added to each well. The plate was then incubated at 37°C for 30 min. Images were taken using a macroscopic CCD camera.
[0142] Results:
[0143] [Figure 9] On both the A1) ELISpot and A2) ELISA plates, wells without diffusion rate limiting media (such as semi-solid media) produced clump-like precipitates in solution. Cells did not form clearly defined spots, therefore quantifiable data could not be obtained. Note: The TMB solution used in this experiment was ELISpot-specific TMB, which formed a precipitate.
[0144] [Figure 9] Countable visible spots (dots) were produced in the wells containing diffusion rate limiting media on both platforms of the ELISpot and ELISA plates. By reducing the diffusion rate of TMB during the reaction, cells locally concentrate the precipitate at the reaction site, resulting in color and visible spots (dots). 0.3% agar / RPMI / TMB diffusion rate limiting media (chromogenic medium) was used on the ELISpot plate (see [Figure 9] Bi). 0.3% agarose / RPMI / TMB diffusion rate limiting media (chromogenic medium) was used on the ELISA plate (see [Figure 9] Bii). Visible spots (dots) were formed on both plates when low concentrations of agar or agarose were used as the base component of the diffusion rate limiting media (chromogenic medium). This demonstrates that the method of the present invention is adaptable to a variety of containers and diffusion rate slowing media.
[0145] [Figure 9] Almost no visible spots (dots) were produced in the wells containing diffusion rate limiting media on both platforms of the ELISpot and ELISA plates (negative control). These negative controls showed that almost no visible spots (background noise) were displayed in the absence of rabbit anti-human CD27 antibody and HRP-conjugated goat anti-rabbit Fc region antibody labeling. More importantly, as seen in the above example, see page 14 / 21 of the specification, CN 121752900 A, it is the presence of cells with specific target markers that triggers the formation of blue dye, showing clearly distinguishable visible spots (dots).
[0146] Conclusion:
[0147] The results from both the ELISpot and ELISA plate platforms show that detectable and quantifiable spots are formed only in the presence of a suitable DRLM. In both cases, the experiment will not produce quantifiable data if a suitable DRLM is not used.
[0148] 3 - Visible Spot Formation and Diffusion Rate
[0149] Objective:
[0150] To demonstrate that the formation of visible spots depends on the diffusion rate.
[0151] Materials:
[0152] Rabbit anti-human CD27 antibody, HRP-conjugated goat anti-rabbit Fc region antibody, and Lymphoprep were purchased from Abogen Biosciences. Phosphate-buffered saline (PBS), fetal bovine serum (FCS), phenol red-containing RPMI 1640, ethylenediaminetetraacetic acid (EDTA), sodium bicarbonate (NaHCO3), and peroxidase inhibitors were purchased from Thermo Fisher Scientific. ELISA plates, trypan blue solution, phenol red-free RPMI 1640, and agar were purchased from Merck / Sigma-Aldrich. ELISA plates were purchased from Jet Biofiltration. 3,3',5,5'-tetramethylbenzidine (TMB) was purchased from McBurtec. Carbopol 940, sodium hydroxide (NaOH), and glycerol were purchased from Acros Organics. Grade I water was generated by Merck Direct-Q® 5 UV.
[0153] The macroscopic CCD camera used for image capture was purchased from Shanghai Renyue Co., Ltd., including the calibration software S-eye. The data processing software, Icy software (including Image J), was downloaded from https: / / icy.bioimageanalysis.org / .
[0154] Method:
[0155] 0.056% Carbopol 940 was prepared by adding 75 mg of Carbopol 940 to 100 mL of pre-boiled ultrapure water at room temperature. The wetting process was carried out overnight using a magnetic stirrer, allowing mixing at maximum speed. The volume of 0.1 M NaOH added to the mixture until pH 7.0 was reached was titrated and recorded (33 mL of 0.1 M NaOH was added to the mixture until pH 7.0 was reached). 75 mg of Carbopol 940 equals 0.056% (w / v) in 133 mL volume. TMB was added to each concentration at a 1:1 ratio before use.
[0156] 4% (w / v) agar was added to the water and autoclaved. The agar was then kept at 80°C until needed. Before use, add appropriate amounts of water and TMB at a 1:1 ratio to each concentration.
[0157] At least 12 hours before the experiment, the ELISA plates were coated with rabbit anti-human CD27 antibody (0.5 µg / 50 µL per well), prepared in phosphate-buffered saline (PBS) at pH 7. The wells were then washed six times with PBS and blocked with RPMI 1640 containing 10% FCS.
[0158] On the day of the experiment, fresh blood samples were collected from volunteers. The blood was immediately diluted (50:50) in RPMI 1640 containing 1 mg / mL EDTA. Note: RPMI 1640 containing phenol red was used for cell culture. Lymphocyte isolation was performed as follows: diluted blood was added above the surface of 10 mL lymphoprep solution, and then the system was closed.Centrifuge at 800g for 30 min under dynamic conditions. Extract the lymphocyte layer using a sterile disposable pipette and add fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 to dilute the lymphocytes containing lymphoprep. Then centrifuge the lymphocytes at 300g for 10 min. Remove the supernatant and add fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3, then centrifuge at 300g for 10 min. Repeat this washing process 3 times.
[0159] Then resuspend the lymphocytes in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. Take 100 µL of resuspended cells and dilute in 900 µL RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (1:10 dilution). Vortex the cells, take 100 µL of this cell suspension and add it to 100 µL trypan blue solution, then vortex it again. Add 20 µL of trypan blue-suspended cells to a Neubauer modified counting chamber and count the cells.
[0160] Seed at 5 x 10⁵ cells / well in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 and incubate at 37°C for 2 hours. After 2 hours, wash the wells six times in warm (37°C) PBS. Positive CD27 cells were further labeled with rabbit anti-human CD27 antibody (0.5 µg / 50 µL per well) prepared in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. One control well was administered only with RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. The plates were then incubated at 37°C for 2 hours. After 2 hours, the wells were washed six times in warm (37°C) PBS.
[0161] The wells were treated with a peroxidase inhibitor at 4°C for 15 min, followed by treatment at room temperature (RT) for 10 min. After peroxidase inhibitor treatment, the wells were washed six times in warm (37°C) PBS. The HRP-conjugated goat anti-rabbit Fc region antibody, prepared by diluting (1:1000) in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3, was added to the sample wells.mg / mL EDTA + 0.2% NaHCO3 was added to the wells of Control 1. The plate was incubated at RT for 1 hour. After 1 hour, the wells were washed six times in warm (37°C) PBS.
[0162] A series of diffusion rate limiting media (DRLM) and PBS (instead of DRLM) as Control 2 were prepared: 0.3%, 1%, and 2% (w / v) agar; 0.028% and 0.014% Carbopol 940; 50% glycerol, all containing 50% TMB. 40 µL of each diffusion rate limiting media (chromogenic media) was added to the appropriate wells and incubated at 37°C for 30 min.
[0163] Results:
[0164] The different DRLMs tested are listed in [Figure 13]. Very few visible background spots (dots) were seen in Control 1, which did not have a reporter enzyme probe added. Note that 9 to 20 spots were considered background positives or false positives, possibly due to endogenous peroxidase activity. In Control 2, a large number of TMB precipitates were observed, but hardly any clearly defined visible spots were formed, so they could not be counted. In the case of agar and carboplatin, a wide range of visible spot counts were observed between the different concentrations used. The average visible spot counts for 2%, 1% and 0.3% w / v agar formulations were 972±451, 1132±219 and 4897±263, respectively. The average visible spot counts for 0.028% and 0.014% w / v carboplatin formulations were 3903±213 and 6553±300, respectively. The 50% glycerol sample showed a very low number of visible spots (ranging from 20 to 28), which was not significantly different from Control 1 and was attributed to the enzymatic stability properties of glycerol. (n=3).
[0165] Control 1, which was not coupled with the enzyme probe, had an average of 14 visible spots, caused by endogenous peroxides known to be expressed in B cells [1]. Peroxide inhibitors did not completely inhibit all endogenous peroxide activity in cells; however, the number of visible spots in Control 1 was still significantly lower than that in wells incubated with the enzyme probe. Control 2, containing PBS and 50% TMB, could not be accurately counted due to excessively large TMB precipitate clumps. Furthermore, the entire solution turned blue / purple. This is because there was no DRLM in the substrate mixture to slow down the substrate / detectable product diffusion rate. The percentage (w / v) of agar and carboplatin greatly affected the visible spot count, with high percentage (w / v) agar (1%–2% w / v) (see [Figure 10]) and carboplatin (0.028% w / v) (see [Figure 11]) concentrations resulting in lower visible spot counts, and vice versa. Slower detectable product diffusion rates allow concentrations around cells to accumulate to visible levels. However, if diffusion...If the diffusion rate is slowed too much, the formation of visible spots will be inhibited, which is likely because the unintended substrate diffusion rate limitation results in insufficient substrate at the reaction site and the product diffusion is too slow to reach the visible size. As shown in Example 1 above, higher concentrations of diffusion rate limiting media give a slower methylene blue diffusion rate. It is important to note that the visible spot count of the 50% glycerol-TMB experiment was similar to that of the negative control, with very few visible and countable spots. Glycerol is known to be an enzyme stabilizer that causes glycerol-induced conformational changes that are responsible for enzyme stability (in enzyme storage) [2] and inhibition (possibly due to the disruption of hydrogen bond networks) [3]. Glycerol is an example of an incompatible medium, being a viscous liquid that can slow diffusion but is incompatible with enzymatic reactions.
[0166] Microscopic studies of the ELISA wells using a top-view microscope (see [Fig. 12]) at 100x magnification showed visible spots (dots) with a deep blue core from which a light blue / green halo radiated. This indicates that each spot was generated by a single cell. Note: The visible spots (dots) are slightly larger than typical lymphocytes; one spot equals one cell.
[0167] Conclusion
[0168] Visible spots (dots) can form in DRLMs such as semi-solid (agar) or viscous liquid (Carbopol), provided the medium is compatible with the experiment. Incompatible media (50% glycerol-TMB) proved unable to form visible spots (dots) due to incompatibility with the enzyme reaction. The composition % (w / v) of the semi-solid or viscous liquid greatly affects the number of visible spots (dots) formed, as the chromogenic substrate diffuses to the enzyme site while the detectable product diffuses from the enzyme site.
[0169] The use of an ELISA plate platform allows for top-view microscopy (unlike the ELISpot platform with a solid membrane at the bottom). Under 100x magnification, the spots (dots) show a dark core, with light blue / green halos representing the concentration of the blue chromogenic product, where the light blue / green halos are the diffusion fronts of the product from the enzyme site. Under 100x magnification, the dots are larger than typical lymphocytes, with one dot representing one cell. References
[0170] 1. Okada, S.S. et al. (2016) 'Myeloperoxidase in human peripheral blood lymphocytes: Production and subcellular localization', Cellular Immunology, 300, pp. 18–25. doi:10.1016 / j.cellimm.2015.11.003.
[0171] 2.Ramm, I. et al. (2021) 'The Impact of Glycerol on an Affibody Conformation and Its Correlation to Chemical Degradation', Pharmaceutics, 13 (11), pp. 1853-1866. https: / / doi.org / 10.3390 / pharmaceutics13111853
[0172] 3. Meneses, L. et al. (2023) 'Improving the activity of horseradish peroxidase in betaine-based natural deep eutectic systems', RSC Sustainability, 1, pp. 886-897. https: / / doi.org / 10.1039 / d2su00127f
[0173] 4- Determination in non-immobilized target organisms (cells)
[0174] Target:
[0175] To demonstrate that the method of the present invention is also applicable to non-immobilized target organisms (cells).
[0176] Materials:
[0177] Rabbit anti-human CD27 antibody, HRP-conjugated goat anti-rabbit Fc region antibody, and Lymphoprep were purchased from Abogen Biosciences. Phosphate-buffered saline (PBS), fetal bovine serum (FCS), phenol red-containing RPMI 1640, ethylenediaminetetraacetic acid (EDTA), sodium bicarbonate (NaHCO3), and peroxidase inhibitors were purchased from Thermo Fisher Scientific. Trypan blue solution, phenol red-free RPMI 1640, and agar were purchased from Merck / Sigma-Aldrich. ELISA plates were purchased from Jet Biofiltration. 3,3',5,5'-tetramethylbenzidine (TMB) was purchased from McBurney. Agarose was purchased from BioBalance.
[0178] The macroscopic CCD camera used for image capture was purchased from Shanghai Renyue Co., Ltd., including the calibration software S-eye. Data processing software, Icy software (including ImageJ), was downloaded from https: / / icy.bioimageanalysis.org / .
[0179] Methods:
[0180] Fresh blood samples were collected from volunteers on the day of the experiment. The blood was immediately diluted (50:50) in RPMI 1640 containing 1 mg / mL EDTA. Note: RPMI 1640 containing phenol red was used for cell culture. Lymphocyte isolation was performed as follows: the diluted blood was added to 10 mL...The lymphocytes were placed above the surface of the lymphoprep solution and then centrifuged at 800g for 30 min with the brake function off. The lymphocyte layer was extracted using a sterile disposable pipette, and fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (page 17 / 21 of the instruction manual, 20 CN 121752900 A) was added to dilute the lymphocytes containing lymphoprep. The lymphocytes were centrifuged at 300g for 10 min. The supernatant was removed, and fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 was added, followed by centrifugation at 300g for 10 min. This washing process was repeated 3 times.
[0181] The lymphocytes were then resuspended in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. Take 100 µL of resuspended cells and dilute in 900 µL RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (1:10 dilution). Vortex the cells, take 100 µL of this cell suspension and add it to 100 µL trypan blue solution, then vortex it again. Add 20 µL of trypan blue-suspended cells to a Neubauer modified counting chamber and count the cells.
[0182] Using 50 mL Falcon tubes, label positive CD27 cells with rabbit anti-human CD27 antibody (0.5 µg / 5 x 10⁵ cells) prepared in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. Negative control cells were only given RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. The labeled cells and negative control cells were then incubated at 37°C for 2 hours. After 2 hours, the cells were pelleted by centrifugation at 300g for 10 min, followed by washing with warm (37°C) PBS and re-precipitating. This cell washing process was repeated 3 times.
[0183] The cells were treated with a peroxidase inhibitor at 4°C for 15 min, followed by treatment at room temperature (RT) for 10 min. After peroxidase inhibitor treatment, the cells were washed by centrifugation at 300g for 10 min, followed by washing with warm (37°C) PBS and re-precipitating. This cell washing process was repeated 3 times.
[0184] The cells were prepared by dilution (1:1000) in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3.HRP-conjugated goat anti-rabbit Fc region antibody was added to rabbit anti-human CD27 antibody-labeled cells, and RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 was added to the negative control wells. The cells were incubated at RT for 1 hour. After 1 hour, the cells were washed by centrifugation at 300g for 10 min, followed by washing with warm (37°C) PBS and allowing them to reprecipitate. This cell washing process was repeated 3 times.
[0185] 0.028% (w / v) Carbopol-TMB was prepared by mixing 0.058% (w / v) Carbopol with TMB at a 1:1 ratio. The TMB solution was tested for specificity for both ELISA and ELISpot assays. The 0.028% (w / v) Carbopol-TMB mixture was added directly to the cell pellet, vortexed, and added directly to a microscope slide (10 µL). The microscope slide was developed at 37°C for 30 min. Images were taken using a macroscopic CCD camera.
[0186] Results:
[0187] As illustrated in [Fig. 14], the unimmobilized CD27-labeled cells showed complete labeling with rabbit anti-human CD27 primary antibody, followed by HRP-conjugated goat anti-rabbit Fc region secondary antibody. Both cases formed dots when mixed with [Fig. 15] A) ELISA-specific TMB and B) ELISpot-specific TMB solutions. Negative controls (unimmobilized unlabeled cells) [Fig. 15] C) ELISA-specific TMB and D) ELISpot-specific TMB solutions showed very few visible spots (background).
[0188] Regarding the microscopic study of the microscope slide [Fig. 16] A), multiple visible spots (dots) were visible at 10x magnification. More importantly, at 100x magnification (Fig. 16B), the visible spots (dots) have a deep blue core, and the light blue / green halo around the visible spots (dots) is the diffusion front. Additionally, the volume covered by the dots is larger than the size of a single cell when compared to nearby non-target cells.
[0189] Conclusion
[0190] The method of the present invention provides visible spots (dots) of non-immobilized cells labeled with a rabbit anti-human CD27 primary antibody, followed by an HRP-conjugated goat anti-rabbit Fc region antibody. Each visible spot (dot) represents a labeled cell generated by an enzymatic reaction from a chromogen to a visible chromophore, in which horseradish peroxidase (HRP) is the enzyme and 3,3',5,5'-tetramethylbenzidine (TMB) substrate is the chromogen. The diffusion front of chromophores with lower concentrations compared to the reaction site (or core) appears as a light blue / green halo, as described on page 18 / 21 of the specification, CN 121752900 A.The color of the surface markers (of the cells) appears as nearly black to dark blue. Due to the diffusion effect of the chromophore radiating outward from the core of the reaction site, the visible spots (dots) are larger than the labeled cells. A direct comparison of CD27-labeled dots with CD27-negative cells shows that the visible spots (dots) are much larger than those of CD27-negative cells. This demonstrates that the diffusion rate limiting medium is essential in the formation of larger, more easily detectable visible spots (dots), and that the color formed is not solely due to cell staining.
[0191] 5 - Specific antigen-targeted memory B cell assay: SARS-CoV-2 spike protein and nucleocapsid protein.
[0192] Objective:
[0193] To detect antigen-specific memory B cells in peripheral blood mononuclear cells (PBMCs) targeting the SARS-CoV-2 spike protein and nucleocapsid protein as models.
[0194] Materials:
[0195] Rabbit anti-human CD27 antibody and Lymphoprep were purchased from Abogen Biosciences. Phosphate-buffered saline (PBS), fetal bovine serum (FCS), RPMI 1640 containing phenol red, ethylenediaminetetraacetic acid (EDTA), sodium bicarbonate (NaHCO3), and peroxidase inhibitors were purchased from Thermo Fisher Scientific. ELISpot plates, trypan blue solution, RPMI 1640 without phenol red, and agar were purchased from Merck / Sigma-Aldrich. 3,3',5,5'-tetramethylbenzidine (TMB) was purchased from McBurney. Biotinylated SARS-CoV-2 spike protein (from Wuhan-Hu-1 isolate) and biotinylated nucleocapsid protein (2019-nCov WHU02 isolate) were purchased from Acro Biosystems.
[0196] The macroscopic CCD camera used for image capture was purchased from Shanghai Renyue Co., Ltd., including the calibration software S-eye. Download the data processing software, Icy software (including Image J), from https: / / icy.bioimageanalysis.org / .
[0197] Methods:
[0198] At least 12 hours before the experiment, ELI Spot plates were coated with rabbit anti-human CD27 antibody (0.5 µg / 50 µL per well), which was prepared in PBS at pH 7. The wells were then washed six times with PBS and blocked with RPMI 1640 containing 10% FCS.
[0199] On the day of the experiment, fresh blood samples were collected from volunteers. The blood was immediately diluted (50:50) in RPMI 1640 containing 1 mg / mL EDTA. Note: RPMI 1640 containing phenol red was used for cell culture. Lymphocyte isolation was performed as follows: diluted blood was added to 10 mL of lymphoprep solution, and then the system was closed.Centrifuge at 800g for 30 min under dynamic conditions. Extract the lymphocyte layer using a sterile disposable pipette and add fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 to dilute the lymphocytes containing lymphoprep. Centrifuge the lymphocytes at 300g for 10 min. Remove the supernatant and add fresh RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3, then centrifuge at 300g for 10 min. Repeat this washing process 3 times.
[0200] Then resuspend the lymphocytes in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. Take 100 µL of resuspended cells and dilute in 900 µL RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 (1:10 dilution). Vortex the cells, take 100 µL of this cell suspension and add it to 100 µL trypan blue solution, then vortex it again. Add 20 µL of trypan blue-suspended cells to a Neubauer modified counting chamber and count the cells.
[0201] Seed at 5 x 10⁵ cells / well in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 and incubate at 37°C for 2 hours. After 2 hours, wash the wells six times in warm (37°C) PBS. Biotinylated SARS-CoV-2 S protein and biotinylated nucleocapsid protein (100 ng / 50 µL each antigen per well) prepared in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 were further labeled with positive CD27 cells. Negative control wells were treated only with RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3. The plates were then incubated at 37°C for 2 hours. After 2 hours, the wells were washed six times in warm (37°C) PBS.
[0202] The wells were treated with a peroxidase inhibitor at 4°C for 15 min, followed by treatment at room temperature (RT) for 10 min. After peroxidase inhibitor treatment, the wells were washed six times in warm (37°C) PBS. The HRP-conjugated streptavidin (1 mg / mL) stock solution was diluted 1:1000 in RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3.Add to the test wells and add RPMI 1640 + 10% FCS + 1 mg / mL EDTA + 0.2% NaHCO3 to the negative control wells. Incubate the plate at 37°C for 45 min. After 45 min, wash the wells six times in warm (37°C) PBS.
[0203] The diffusion rate limiting medium (DRLM) consisting of agar, ELISpot-specific TMB and phenol red-free 4x RPMI was prepared as follows: Take 4x RPMI: 1.2% agar (warmed to 80°C) in a 1:1:2 ratio: reserve TMB solution to obtain 0.3% agar / RPMI-TMB semi-solid medium. Add 40 µL of semi-solid TMB medium to each well. Then incubate the plate at 37°C for 30 min. Take pictures using a macro CCD camera.
[0204] Results:
[0205] CD27 positive cells were immobilized on the experimental wells with rabbit anti-human CD27 antibody. These immobilized CD27-positive cells from peripheral blood samples included T cells[1][3], natural killer cells[2][3], memory B cells, and plasma cells, but not naive B cells[4]. Negative control cells were not labeled with SARS-Cov-2 spike protein and nucleocapsid protein (see Fig. 17A). SARS-Cov-2 specific memory B cells were labeled with biotinylated SARS-Cov-2 spike protein and nucleocapsid protein (see Fig. 17B). Of all the immobilized CD27+ cells, only those expressing B cell antigen receptor (BCR) could directly bind to the target antigen without MHC molecules[5][6]. Plasma B cells lack surface immunoglobulin expression[7], which makes memory B cells the only cells immobilized on the surface of plates expressing BCR that can be tagged with antigen-enzyme probes and generate visible spots. Clearly, some background spots were visible in the negative control test, but significantly more visible spots were visible in the test wells, as confirmed by the visible spot counts shown in Table 2 and the histogram of data in [Figure 18].
[0206] [Table 2] summarizes the visible spot counts for each test well shown in [Figure 17], including the mean and standard deviation of three replicates (n=3).
[0207] Conclusion
[0208] In this study, a direct method for detecting antigen-specific memory B cells in peripheral blood using the method of the present invention is provided. The method is able to determine the frequency of SARS-Cov-2 antigen-specific memory B cells against the SARS-Cov-2 spike protein and nucleocapsid protein in whole peripheral blood mononuclear cells (PBMCs) (mean antigen-specific memory B cell spot count (29) – mean negative control (7) = 22 / 5 x 105 x 100 = 0.0044%). This is consistent with literature work: depending on the vaccineLimiting dilution analysis of the frequency of antibody-secreting cell precursors, based on inoculation status and the size / number of epitopes present on the antigen, showed results between 0.05% and 0.005% [8]. References
[0209] 1. Hintzen, RQ et al. “Regulation of CD27 expression on subsets of mature T-lymphocytes.” Journal of immunology (Baltimore, Md.: 1950) vol. 151,5 (1993): 2426-35.
[0210] 2. Silva, Anabel et al. “Application of CD27 as a marker for distinguishing human NK cell subsets.” International immunology vol. 20,4 (2008): 625-30. doi:10.1093 / intimm / dxn022.
[0211] 3. Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al‑Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell. 2017 Dec 11;32(6):777‑791.e6. doi: 10.1016 / j.ccell.2017.11.001. Epub 2017 Nov 30. PMID: 29198913; PMCID: PMC5734932.
[0212] 4. Levesque, Marc C, and E William St Clair. “Bcell‑directed therapies for autoimmune disease and correlates of disease response and relapse.” The Journal of allergy and clinical immunology vol. 121,1 (2008): 13‑21; quiz 22‑3. doi:10.1016 / j.jaci.2007.11.030
[0213] 5 .Alberts B , Johnson A , Lewis J , et al . Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. T Cells and MHC Proteins.
[0214] 6 .Paul S , Lal G . The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol. 2017 Sep 13;8:1124. doi: 10.3389 / fimmu.2017.01124. PMID: 28955340; PMCID: PMC5601256.
[0215] 7 .Ribatti , D. (2017) . The discovery of plasma cells: An historical note . Immunology Letters , 188 , pp .64–67 . doi:https: / doi .org / 10 .1016 / j.imlet.2017.06.006.
[0216] 8.Smith MJ , Packard TA, O 'Neill SK , Hinman RM , Rihanek M , Gottlieb PA, Cambier JC. Detection and Enrichment of Rare Antigen‑specific B Cells for Analysis of Phenotype and Function. J Vis Exp. 2017 Feb 16;(120):55382.doi: 10.3791 / 55382. PMID: 28287549; PMCID: PMC5409333. Instruction manual 21 / 21 pages, 24 CN 121752900 A Figure 1, Instruction manual drawing 1 / 19 pages, 25 CN 121752900 A Figure 2A, Instruction manual drawing 2 / 19 pages, 26 CN 121752900 A Figure 2B, Instruction manual drawing 3 / 19 pages, 27 CN 121752900 A Figure 2C, Instruction manual drawing 4 / 19 pages, 28 CN 121752900 A Figure 3, Instruction manual drawing 5 / 19 pages, 29 CN 121752900 A Figure 4A, Instruction manual drawing 6 / 19 pages, 30 CN 121752900 A Figure 4B, Instruction manual drawing 7 / 19 pages, 31 CN 121752900 A Figure 4C Instruction Manual Figure 8 / 19, Page 32, CN 121752900 A, Figure 5A; Instruction Manual Figure 9 / 19, Page 33, CN 121752900 A, Figure 5B; Instruction Manual Figure 10 / 19, Page 34, CN 121752900 A, Figure 6, Figure 7; Instruction Manual Figure 11 / 19, Page 35, CN 121752900 A, Figure 8, Figure 9; Instruction Manual Figure 12 / 19, Page 36, CN 121752900 A, Figure 10, Figure 11; Instruction Manual Figure 13 / 19, Page 37, CN 121752900 A, Figure 12; Instruction Manual Figure 14 / 19, Page 38, CN 121752900 A, Figure 13; Instruction Manual Figure 15 / 19, Page 39, CN 121752900 A, Figure 14, Figure 15; Instruction Manual Figure 16 / 19, Page 40, CN 121752900 A, Figure 16. Instruction manual figures 17 / 19, page 41, CN 121752900 A; Figure 17; Instruction manual figures 18 / 19, page 42, CN 121752900 A; Figure 18; Instruction manual figures 19 / 19, page 43, CN 121752900 A
Claims
1. A method for detecting a target organism in a sample, the method comprising: a. Optionally, the target organism is fixed onto a solid phase; b. Incubate the target organism with one or more reporter enzyme detection probes to form one or more target organism-enzyme detection probe complexes; c. Remove any unbound reporter enzyme detection probes; d. Contacting the one or more target organism-enzyme detection probe complexes with a diffusion rate limiting medium containing one or more substrates, and incubating the one or more target organism-enzyme detection probe complexes and the one or more substrates in the diffusion rate limiting medium to generate one or more detectable products; and e. Detecting one or more detectable products by detecting visible spots; The diffusion rate limiting medium is any suitable medium that reduces the diffusion rate of the one or more detectable products and thereby allows the formation of the visible spots.
2. The method of claim 1, wherein step b) comprises incubating the target organism with one or more primary detection agents specific to the target organism before incubating it with the one or more reporter enzyme detection probes to form the one or more target organism-enzyme detection probe complex.
3. The method of claim 2, wherein the one or more primary detection agents bind to one or more surface ligands of the target organism, one or more surface markers of the target organism, or one or more target substances secreted by the target organism, and wherein the primary detection agent is an antibody or its binding fragment, or an antigen.
4. The method of any one of claims 1 to 3, wherein if the target organism expresses an endogenous enzyme that is the same as or similar to the reporter enzyme of the one or more reporter enzyme detection probes, then step b) further comprises contacting the target organism with an inhibitor of the endogenous enzyme.
5. The method of any one of claims 1 to 4, wherein the target organism is a cell or a portion thereof, or a microorganism or a portion thereof.
6. The method of any one of claims 1 to 5, wherein the solid phase is a reaction vessel, bead, or plate, and wherein the surface of the solid phase is selected from metals, gold, stainless steel, plastics, glass, silica, polycarbonate, polyester, PVDF, polystyrene, nitrocellulose, and cellulose.
7. The method of any one of claims 1 to 6, wherein the target organism is immobilized by directly binding to the solid phase, or indirectly immobilized to the solid phase by a capture molecule coupled to the solid phase in which the target organism is bound.
8. The method of claim 7, wherein the capture molecule is an antibody, an antigen, or a ligand.
9. The method of any one of claims 1 to 8, wherein the diffusion rate limiting medium is a semi-solid medium, a film, or a viscous fluid.
10. The method of claim 9, wherein the semi-solid medium is selected from the group consisting of agar, agarose, hydrogel, gelatin, silicone gel, cellulose derivative and SDS-PAGE gel.
11. The method of claim 9, wherein the membrane is selected from the group consisting of paper membranes, fiber membranes, cellulose membranes, and plastic membranes.
12. The method of claim 9, wherein the viscous fluid is selected from the group consisting of cellulose derivatives, polysaccharide or monosaccharide gels (syrups, low-concentration hydrogels, cassava gels, guar gum, xanthan gum, gum arabic, hydroxyethyl cellulose, HPC (hydroxypropyl cellulose)) and low-concentration hydrogels.
13. The method of any one of claims 1 to 12, wherein the one or more reporter enzyme detection probes bind to one or more surface ligands of the target organism, one or more surface markers of the target organism, one or more target substances secreted by the target organism, or the one or more primary detection agents, and wherein the reporter enzyme detection probes are selected from antibodies or their binding fragments, antigens, drugs, or peptides, which are directly or indirectly conjugated to an enzyme or catalyst that can change color upon contact with a substrate.
14. The method of any one of claims 1 to 13, wherein the substrate is selected from the group consisting of tetramethylbenzidine (TMB), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), p-nitrophenol (PNPP), 3,3'-diaminobenzidine (DAB), 4-(trifluoromethyl)umbelliferyl ketone phosphate, 4-methylumbelliferyl ketone β-D-galactopyranoside (Mu-Gal), adamantyl 1,2-dioxane phosphate, o-Nitrophenyl-β-D-galactopyranoside (ONPG), Nitroblue tetrazolium (NBT), 2,2'-bis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), Nitroblue tetrazolium chloride (NBT), N-acetyl-Leu-Glu-His-Asp-7-amino-4-trifluoromethylcoumarin, N-acetyl-Leu-Glu-Thr-Asp-7-amino-4-trifluoromethylcoumarin, and 3-oxo-3H-phenoxazine-7-yl-butyrate (butyrate halogen).
15. A method for quantifying the amount of a target organism in a sample, the method comprising: a. Detecting the target organism according to the method of any one of claims 1 to 14; and b. Quantify the amount of the target organism in the sample based on the number of visible spots.
